Negative modulation of AR activity, whose aberrant activity is commonly associated with prostate cancer, similarly suggests a role for AES/GRG5 in certain cancers independent of its dominant-negative activity over long TLE/GRG proteins (Yu et al., 2001; Baniwal et al., 2009; Zhang et al., 2010). The gene discussed is TLE5; the disease is prostate carcinoma.